Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Jun 27th, 2:10 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 33.59 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Research Links Key Proteins to the Growth of Brain Tumors
University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive.
Via Investor Brand Network · June 27, 2025
According to recent industry data, interest in pre-owned vehicles has surged due to ongoing supply chain constraints affecting new car production and rising inflation rates. Select Automotive’s latest move positions the dealership as a key player in addressing this gap, with dozens of new arrivals added to its lot this month alone.
Via Get News · June 27, 2025
BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare
Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.”
Via Investor Brand Network · June 26, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.
Via Investor Brand Network · June 26, 2025
Why Public Interest in Mitochondrial Function Testing is Growing
Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested?
Via Investor Brand Network · June 26, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus” , confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.
Via Investor Brand Network · June 26, 2025
BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Partners with Endlink to Advance Hospital Data Integration
HealthLynked (OTCQB: HLYK), a healthcare technology and patient engagement company, has announced a strategic partnership with Endlink, a data integration firm led by Rubén Viera. The alliance aims to enhance EMR connectivity and workflow automation across hospital systems, building on Endlink’s success in Puerto Rico, where its platform serves over 300,000 members and supports two major hospital systems. Viera, a former executive at McKesson and Greenway Health, brings over 25 years of experience in healthcare IT and will help expand HealthLynked’s capabilities in real-time data integration and patient-centered care. The collaboration also creates opportunities to deploy HealthLynked’s tools—like AI-driven insights and virtual care access—across Endlink’s client base.
Via Investor Brand Network · June 25, 2025
Limo SF VIP (888-888-0195) announces a new premium chauffeur service offering executive travelers seamless and exclusive transportation in and around San Francisco.
Via Press Release Distribution Service · June 24, 2025
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal studies. InMed plans to advance INM-901 through additional preclinical and IND-enabling studies with a lead indication in Alzheimer’s disease.
Via Investor Brand Network · June 24, 2025
Panda Hub, a mobile-first car detailing marketplace, has expanded into 15 U.S. states and 2 Canadian provinces. The platform connects vehicle owners with certified detailers for on-site interior and exterior services. Customers can book directly online and receive professional car care at their home, workplace, or other approved location. This expansion reflects Panda Hub’s ongoing mission to deliver consistent, transparent, and eco-conscious detailing services across North America.
Via Get News · June 24, 2025
Could Wheat Germ Hold the Key to Supercharging Immunotherapy? New Research Hopes to Find Out
An ongoing clinical trial at the Comprehensive Cancer Center at UC Davis seeks to find out whether fermented wheat germ could help cancer patients undergoing immunotherapy have better outcomes and live full lives, or even beat cancer.
Via Investor Brand Network · June 24, 2025
How Robotics Technology is Transforming Healthcare
Robotics is playing an ever-increasing role in revolutionizing healthcare . The medical industry is playing a leading role in the adoption of robotics and the pace at which these technologies are being adopted is accelerating. It is therefore not surprising that the market for medical robotics is forecast to grow from $16.6bn to $63.8bn between 2023 and 2032. Several applications of these technologies are justifying further deployment.
Via Investor Brand Network · June 20, 2025
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic opioids like fentanyl. The crisis is evolving, not disappearing, and the pharmaceutical industry continues to grapple with the challenge of balancing patient access with the need for safety and deterrence.
Via Investor Brand Network · June 20, 2025
Not Your Basic Locksmith (817-508-2601) expands its mobile automotive locksmith services, now available across the greater Dallas-Fort Worth metroplex, including Mansfield, Irving, Keller, Bedford, and Hurst.
Via Press Release Distribution Service · June 20, 2025
Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a novel treatment currently undergoing Phase 2a clinical trials aimed at addressing mild to moderate psoriasis.
Via Investor Brand Network · June 18, 2025
Doylestown Auto Repair (267-279-9477) has expanded their specialized timing chain and brake replacement services for Audi vehicles, providing affordable, high-quality repairs.
Via Press Release Distribution Service · June 18, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing process scale-up of its lead product, Aversa Fentanyl, in collaboration with Kindeva, a global CDMO specializing in drug-device combinations. Aversa Fentanyl integrates Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch and is produced at Kindeva’s U.S.-based transdermal facility. The next step involves producing clinical supplies and submitting an Investigational New Drug application to begin a human abuse liability study. Nutriband projects Aversa Fentanyl, which aims to be the world’s first abuse-deterrent opioid patch, could achieve peak U.S. sales between $80 million and $200 million, with broader global market ambitions supported by its extensive international patent portfolio.
Via Investor Brand Network · June 18, 2025
Study Finds the Overall Prevalence of Psoriasis in the US Unchanged
A recently published analysis that appeared in the Journal of American Academy of Dermatology has concluded that the general percentage of adults in the U.S. diagnosed with psoriasis remains unchanged at 3% over the past 10 years. However, the investigators mention several points of concern that aren’t reflected in this general summary.
Via Investor Brand Network · June 17, 2025
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies, notably SGX945 (dusquetide), aiming to address the unmet need in this challenging disease landscape ( https://ibn.fm/KByRu ).
Via Investor Brand Network · June 17, 2025
OTOFIX has just introduced the D1 Lite, a compact diagnostic tool designed for small garages, mobile technicians, and students in training. Available at https://otofix.store , it offers key diagnostic features typically found in higher-end models at a price point meant to support independent repair professionals and learners alike.
Via Get News · June 16, 2025
SLRspeed Launches New Performance Upgrades to Dominate the 2025 Drift and Street Scene
June 13, 2025 - Stuart, FL, USA - SLRspeed, a leader in precision-engineered drifting and racing parts, continues to push the boundaries of performance in 2025 with expanded product lines and technical resources aimed at enthusiasts, professionals, and DIY builders alike.
Via AB Newswire · June 13, 2025
CHIGEE, a pioneer in smart mobility, has officially launched the AIO-5 Smart Riding System—marking a significant leap forward in the integration of motorcycle technology with real-world riding needs.
Via AB Newswire · June 13, 2025
New Study Shows TTFields Amplify Immune Attack Against Brain Cancer
Breakthrough research conducted by a team at the University of Southern California (USC) has found that electric fields, administered through a device placed on a patient’s scalp, can supercharge the immune system’s ability to combat glioblastoma and increase the survival time of the patient.
Via Investor Brand Network · June 13, 2025
Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development
A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates.
Via Investor Brand Network · June 12, 2025
Study Finds Kids with MS Biologically Age Faster Than Those Without It
New research conducted by UC San Diego researchers has revealed that adolescents and children having multiple sclerosis exhibit accelerated biological ageing . These findings were published in the journal Neurology . This study suggests that the changes linked to ageing could be happening earlier than had initially been thought among patients with MS.
Via Investor Brand Network · June 12, 2025